ArticleNature chemical biology2025
Functional targeting of membrane transporters and enzymes to peroxisomes.
Article in Nature chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Engineered peroxisomes hold promise as a highly versatile platform for compartmentalizing engineered metabolic pathways, insulating them from native cellular factors to prevent undesired crosstalk. However, native peroxisomes often lack the required substrates and cofactors in their lumen; accordingly, nonnative membrane proteins (MPs) must be recruited to the peroxisomal membrane to support heterologous pathways requiring these molecules. We developed a robust, modular 'chauffeur' strategy that enables MP folding in the endoplasmic reticulum (ER) followed by trafficking to the peroxisomal membrane through an engineered interaction in the cytosol with a transmembrane domain natively trafficked from the ER to the peroxisome. We demonstrate the modularity of this strategy by successfully redirecting multiple MP cargoes, including heterologous plant MPs, and observed increased titers for a monoterpene biosynthetic pathway. This strategy overcomes the challenges of misfolding and sorting of MPs to the peroxisome and, accordingly, expands the repertoire of pathways that can be compartmentalized into this organelle.
Indexed as
Identifiers
40524007What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.